Is the use of Ro 10-9359 (Tigason) in children justified?
- PMID: 6158237
Item in Clipboard
Is the use of Ro 10-9359 (Tigason) in children justified?
Acta Derm Venereol.
1980.
Abstract
In 5 children ranging in age from 8 to 12 years, treatment with Ro 10-9359 for either psoriasis or erythrokeratodermia variabilis for periods of between 11 and 17 months did not cause marked growth retardation and gave excellent therapeutic results.
Similar articles
-
Pilot study of a new retinoid, Ro 12-7554, in psoriasis and in some congenital disorders of keratinization.Dermatologica. 1983;167(1):52-3. doi: 10.1159/000249746. Dermatologica. 1983. PMID: 6226548
-
[Mendes Da Costa erythrokeratoderma variabilis. Effect of RO 10-9359 (Tigason)].Ann Dermatol Venereol. 1988;115(11):1123-5. Ann Dermatol Venereol. 1988. PMID: 2977072 French. No abstract available.
-
[A case of erythrokeratodermia figurata variabilis successfully treated with tigason].Z Hautkr. 1989 Oct 15;64(10):881-2, 885-7. Z Hautkr. 1989. PMID: 2531508 German.
-
[Treatment of erythrodermic and pustulous psoriasis with a combination of methotrexate and etretinate].Med Cutan Ibero Lat Am. 1988;16(1):43-9. Med Cutan Ibero Lat Am. 1988. PMID: 2967409 Review. Spanish.
-
International studies of the efficacy of etretinate in the treatment of psoriasis.J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):692-6. doi: 10.1016/s0190-9622(82)70058-1. J Am Acad Dermatol. 1982. PMID: 7040512 Review.
Cited by
-
Psoriasis in children: an insight.Indian J Dermatol. 2011 May;56(3):262-5. doi: 10.4103/0019-5154.82477. Indian J Dermatol. 2011. PMID: 21772584 Free PMC article.
-
Etretinate therapy in children with severe keratinization defects.Eur J Pediatr. 1985 Jan;143(3):166-9. doi: 10.1007/BF00442128. Eur J Pediatr. 1985. PMID: 2580708 Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials